Hematopoietic stem cells (HSCs) are the self-renewing multipotent progenitors to all blood cell types. Identification and isolation of HSCs for study has depended on the expression of combinations of surface markers on HSCs that reliably distinguish it from other cell types. However, the increasing number of markers required to isolate HSCs has made it tedious, expensive, and difficult for newcomers, suggesting the need for a simpler panel of HSC markers. We previously showed that phenotypic HSCs could be separated based on expression of CD11a, and that only the CD11a negative fraction contained true
Introduction
Hematopoietic stem cells (HSCs) are the self-renewing, multipotent, and engraftable cells of the blood system [1] . Successful HSC transplantation (HSCT) can potentially treat any disorder inherent to the hematopoietic system by ablation of the defective blood system followed by reconstitution by healthy donor HSCs [2] . However, HSCT is reserved only for high-risk patients due to the dangers of HSCT-related complications, including graft rejection, graft failure, and graft versus host disease [2] .
Transplantation of sufficient numbers of pure HSCs can bypass many of these HSCTrelated complications [3] [4] [5] . Therefore, much effort has been invested in strategies to improve the purity of donor HSCs.
HSCs are identified by their expression of a combination of molecules on their cell surface called surface markers. In mice, the ever-growing list of surface markers whose positive or negative expression marks HSCs includes CD34, Kit, Sca-1, Lineage (a cocktail of markers of mature lineages), CD27, CD48, CD150, FLK2, CD9, EPCR and others [6] [7] [8] [9] . The marker combination Kit+ Lineage-Sca-1+, which defines the "KLS" population (also called "LSK" or "KSL"), contains all HSCs and multipotent progenitors in the bone marrow (BM). To isolate long-term HSCs within the KLS population, additional marker combinations are needed such as 1) Flk2+ CD34-, 2) CD48-CD150+, or 3) CD150+ CD34- [6, 10, 11] . However, the increasing number of markers needed to purify HSCs (currently around [6] [7] [8] , the nuances of each of the fluorochromes and antibodies required for optimal staining and gating, and the long and expensive assays needed for gating validation have made it difficult for newcomers to properly identify and sort HSCs. Furthermore, many of these markers can change expression during stressful conditions such as upon inflammation or after irradiation, making many of them unreliable for identifying HSCs in these contexts [12] [13] [14] . Therefore, there remains a need for simpler and more inclusive strategies for marking and identifying HSCs in healthy and challenged BM.
We previously introduced CD11a as a new marker to isolate HSCs. CD11a
(integrin alpha L, or Itgal) heterodimerizes with the β2 integrin CD18 to form LFA1.
LFA1 interacts with ICAM-1 and has roles in transendothelial migration, activation, and differentiation of lymphocytes [15] [16] [17] [18] . We found that while CD11a is expressed on nearly all hematopoietic lineages, it is downregulated in HSCs [19] . We showed that stringently-gated adult HSCs can be separated into CD11a+ and CD11a-fractions, with only the CD11a-fraction showing long-term engraftment upon transplantation. This was not due to antibody binding to the CD11a+ cells (potentially blocking LFA1-mediated migration), as inclusion of the CD11a antibody affected neither BM homing, nor longterm engraftment of HSCs. These findings suggested that CD11a should be added to the marker panel when isolating HSCs at the highest level of purity. Here, we introduce an alternative strategy for identification and sorting of HSCs with the use of CD11a and EPCR (endothelial protein C receptor, Procr, CD201) as another efficient HSC marker.
We show that CD11a and EPCR can be used with classical HSC markers to purify HSCs, but furthermore, can be used alone as a simple two-color method to highly enrich for HSCs.
Materials & Methods

Mice
C57Bl/6 (stock no. 00664), CK6/ECFP (TM5; stock no. 004218), and mT/mG (stock no. 007576) strains from Jackson Laboratory (Bar Harbor, ME, USA) were utilized as donors/recipients/helpers. All strains were maintained at the Gross Hall and Med Sci A vivarium facilities at UCI and fed with standard chow and water. All animal procedures were approved by the International Animal Care and Use Committee (IACUC) and University Laboratory Animal Resources (ULAR) of University of California, Irvine.
Antibodies
For list of antibodies, refer to Table S1 ("Antibodies Table" ) in Supporting Information.
Cell sorting
For flow cytometry, BM was harvested from tibias and femurs by flushing with ice-cold FACS buffer (PBS + 2% fetal bovine serum) followed by red blood cell lysis by ACK lysing buffer and filtration through a 70 µ mesh. BM was harvested from donor mice by crushing leg bones in ice-cold FACS buffer followed by red blood cells lysis by ACK lysing buffer and filtration through a 70 µ mesh to remove debris. Where indicated, BM was Kit enriched using anti-Kit (anti-CD117) microbeads on an AutoMACS (Miltenyl Biotec). Cells were stained with antibodies listed in Table S1 ("Antibodies Table" ) in FACS buffer. Cells were sorted on a BD FACS-Aria II (Becton Dickinson) into ice-cold FACS buffer for transplantation.
Transplantation, and blood and BM analysis
Defined numbers of HSCs (as indicated in each experiment) were transplanted by retroorbital injection into lethally-irradiated isoflurane-anesthetized recipients alongside helper BM from congenically distinguishable C57BL/6 mice. Lethal doses of X-ray irradiation were 800 Rads for single dose, or 950 Rads split dose (XRAD 320, Precision X-ray). Transplanted recipients were fed an antibiotic chow of Trimethoprim Sulfa 
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 software (La Jolla, CA).
Results
CD11a and EPCR in combination with classical HSC markers reveal a distinct population with enriched HSC activity
CD11a and EPCR have each been shown independently to increase HSC purity when used with conventional HSC markers [19] [20] [21] . To assess the efficiency of purifying HSCs using CD11a and EPCR together, we first examined their expression in the KLS population, which contains all hematopoietic stem and multipotent progenitor cells and is often referred to as "HSPCs" (Fig. 1) . KLS is traditionally defined as Kit+ Lin-Sca-1+, but we substituted CD27 for the Lineage (Lin) cocktail, an expensive combination of markers for mature hematopoietic lineages. CD27 is expressed on HSCs and MPPs, and together with the red blood cell marker Ter119, can be used in place of Lin [14, 22, 23] .
Within the KLS population (Ter119-CD27+ Sca-1+ Kit+), we identified two distinct fractions: a CD11a-EPCR+ population and a CD11a+ population (Fig. 1A) . We sorted these two populations (from CFP+ donor mice) and transplanted them into lethallyirradiated Bl/6 adult recipients to determine which population contained long-term engraftable HSCs. 500,000 BM cells from Tomato+ mice were co-transplanted as "helper" BM to protect the recipients from hematopoietic failure following irradiation.
Recipients were bled and analyzed for donor chimerism in different blood lineages at four-week intervals (Supporting Information Fig. S1 ). Donor chimerism of total blood cells (CD45+) was significantly higher from the CD11a-EPCR+ KLS population than the CD11a+ KLS population, and this difference increased over time (Fig. 1B) . Because granulocytes are short-lived, granulocyte chimerism in the peripheral blood is a more accurate indicator of HSC chimerism in the BM compared to total CD45+ blood cells, which includes long-lived lymphocytes that may have come from lymphoid progenitors or multipotent progenitors. The difference in granulocyte chimerism between CD11a-EPCR+ KLS cells and CD11a+ KLS was even more pronounced than total blood chimerism (Fig. 1C) . Furthermore, when examining the BM of the recipients, the CD11a-EPCR+ KLS population had higher donor HSPCs (Fig. 1D) . As only HSCs are capable of serial transplantation, we next transplanted whole BM from the primary recipients into secondary hosts. Only the BM of recipients of CD11a-EPCR+ KLS cells gave rise to robust donor chimerism in the secondary hosts, indicating that nearly all HSCs are contained in this population (Fig. 1E) . Thus, CD11a and EPCR can be used to isolate HSCs within the KLS fraction of BM.
CD11a-EPCR+ KLS directly outcompetes CD11a+ KLS in a competitive transplantation assay
To directly compare HSC activity between the CD11a-EPCR+ and CD11a+ subsets of KLS cells, we performed a competitive transplantation, in which both populations are co-transplanted into the same recipients. In this strategy, recipient mice receive both populations at their physiological ratios, providing a direct comparison of the engraftment efficiency of each. Also, because all KLS cells fall within one fraction or the other, all potential sources of HSCs in the BM are sorted and transplanted. To distinguish the two populations, we sorted one population from CFP-expressing BM, and the other population from Tomato-expressing BM and co-transplanted them along with 100,000 unlabeled Bl/6 helper BM cells ( Fig. 2A) . In the peripheral blood of the primary recipients, drastically higher percentages of donor total CD45+ cells and granulocytes were derived from the CD11a-EPCR+ KLS compared to the CD11a+ KLS source ( Fig. 
2B-C).
Higher donor chimerism of HSCs in the BM compartment of primary recipients as well as blood granulocyte chimerism in secondary recipients also originated only from the CD11a-EPCR+ KLS donor source, indicating that this population contained all the HSCs (Fig. 2D-E) .
We also examined the distribution of lineages derived from the two populations (Supporting Information Fig. S2 ). CD11a+ KLS-derived cells showed a lymphoid bias due to significantly higher production of B cells when compared to CD11a-EPCR+ KLS and non-transplanted controls. This lymphoid bias suggests the CD11a+ KLS fraction contained mostly progenitors that predominantly give rise to long-lived B lymphocytes.
These results indicate that essentially all HSCs within the KLS population are CD11a-EPCR+.
CD11a and EPCR alone can enrich HSCs without the need for other HSC markers
We next tested whether CD11a and EPCR alone were sufficient to sort HSCs in the absence of all other HSC markers. We used only these two markers for a competitive transplantation assay, and did not include any other HSC markers. We sorted CD11a-EPCR+ ("11a/EPCR") cells into one tube, and all other live cells (referred to as "Not 11a/EPCR") into another tube, then co-transplanted one population from CFP+ BM and the other population from Tomato+ BM into the same recipient mice. By sorting all cells outside of the CD11a-EPCR+ gate, we could ensure that any potential HSCs that fall outside of the CD11a-EPCR+ population would be transplanted in the "Not 11a/EPCR" fraction. We sorted and transplanted 500,000 BM cells per recipient, but maintained the physiological ratios of CD11a-EPCR+ cells (~0.17% of whole BM; WBM) and Not 11a/EPCR (~99.1% of WBM) (Fig. 3A) . Thus, the transplanted cells are the equivalent of 500,000 WBM cells, with the CD11a-EPCR+ cells distinguishable from the rest of the BM cells by CFP or Tomato expression. In the recipient mice, we found that only the CD11a-EPCR+ donor source showed donor chimerism in primary and secondary recipients ( Fig. 3B-C) . We also examined the BM and found that donor HSPCs were only derived from the CD11a-EPCR+ source (Fig. 3D) . These results indicate that all HSCs are present in the rare CD11a-EPCR+ fraction of BM, and that CD11a and EPCR together are sufficient to sort an enriched HSC population. Fig. S3A) . It was previously shown that HSCs are CD150+ CD48-, and thus there are likely non-HSCs within the CD11a-EPCR+ fraction. The SLAM markers CD150 and CD48 have also been shown to be sufficient for two-color sorting of HSCs [6] . However, when examining the SLAM fraction (CD150+ CD48-) of BM, only 11% of these cells were Kit+ Sca-1+, and only 7.2% were CD11a-EPCR+. To confirm the efficiency of the SLAM method to purify HSCs in our hands, we transplanted CD150+ CD48-(SLAM) and "Not" CD150+ CD48-(referred to as "Not SLAM") in a competitive setting, and found that only the SLAM cells were able to engraft long-term (Supporting Information Fig. S3B-D) . Thus, it appears likely that all HSCs are contained within the SLAM population, but there are also many non-HSCs in this population.
To directly compare our "11a/EPCR" two-color sorting method with the SLAM method, CD11a-EPCR+ (11a/EPCR) and CD150+ CD48-(SLAM) cells were sorted, mixed, and co-transplanted into recipients in a competitive setting (Fig. 4A, Group 1 recipients). Equal numbers of each population (380 cells) were transplanted, allowing us to directly compare which population contained the most HSCs. While at week 4 the 11a/EPCR population had greater granulocyte chimerism than SLAM, after week 4 no statistical difference in granulocyte chimerism between the two populations was detected in primary and secondary recipients (Fig. 4Bi) . Analysis of HSPCs in the BM also confirmed comparable engraftability between the two populations (Fig. 4Bii) . Total blood chimerism and lineage distribution was not significantly different between the two sorting methods in primary and secondary recipients (Supporting Information Fig. 
S4A-B).
To determine whether any HSCs resided outside of the CD11a-EPCR+ or the CD150+ CD48-gates, we sorted each of the "Not" populations ("Not 11a/EPCR" and "Not SLAM") and co-transplanted them into recipient mice (Fig. 4A, Group 2 recipients). Even though we detected significantly higher "Not SLAM"-derived granulocytes compared to "Not 11a/EPCR" at week 4 post-transplant, at later timepoints and in secondary transplants, no significant difference was detected between the two methods (Fig. 4Ci) . This indicates that no HSCs are found outside of the SLAM or 11a/EPCR fractions. However, we found high total chimerism and lymphocyte chimerism from the Not SLAM population, suggesting multipotent and lymphocyte progenitors were highly enriched in this population (Supporting Information Fig. S4C ).
Our data indicate that both two-color strategies are effective at sorting HSCs, although neither is pure for HSCs.
CD11a and EPCR combination identifies phenotypic HSCs following irradiation, but not in inflammation
Many common HSC markers change their expression when challenged, such as during an inflammatory response. Thus, the phenotypic definition of HSCs can change depending on the context. We sought to determine the expression levels of CD11a and EPCR and their ability to mark HSCs after two types of challenge: irradiation and LPS-induced inflammation (Fig. 5) . We sub-lethally irradiated (6 Gy) Bl/6 mice and examined their BM 48 hours post-irradiation. Consistent with previous observations, we detected a dramatic decrease in Kit expression [12, 14] , reducing the frequency of KLS cells (Fig.   5A ). The percentage of CD11a+ cells appeared to increase slightly after irradiation, though EPCR expression appeared unchanged (Fig. 5B, Supporting Information Fig.   S5A ). Other HSC markers also appeared unchanged, with the exception of CD48 which decreased after irradiation (Supporting Information Fig. S5A ). Although CD11a expression appeared to increase overall in the irradiated BM, phenotypic HSCs were still found in the CD11a-EPCR+ fraction, suggesting these markers could still identify HSCs after irradiation (Fig. 5C, Supporting Information Fig. S5B ).
We also examined CD11a and EPCR expression after LPS-induced inflammation, which is known to upregulate Sca-1 and therefore make HSC identification more difficult [24, 25] . While CD11a expression appeared unchanged in LPS-treated BM, EPCR expression changed significantly, and thus we were unable to use this marker combination to identify phenotypic HSCs in this context (Supporting Information Fig.   S6 ). CD11a could still be combined with other HSC markers that appeared unchanged in inflammation, including CD27 and Kit. Future transplantation experiments would be required to confirm whether the phenotypic HSCs identified in either irradiation or inflammation are in fact functional HSCs.
Discussion
Here, we demonstrate a novel strategy for a simplified, reproducible, and efficient way for HSC sorting with the use of CD11a and EPCR. Our transplantation strategy used direct competition between the two KLS fractions as the primary method to evaluate which fraction contained the most HSCs. Methods like limit dilution assays and single cell transplantation assays can provide quantitative estimates of the number of HSCs in a population. While we did not perform those types of assay, in our system we transplanted all possible sources of HSCs at their physiologic proportions into each recipient. Thus, if more HSCs existed outside of the CD11a-EPCR+ fraction, then the "Not CD11a-EPCR+" fraction would have shown higher donor chimerism. The fact that little granulocyte chimerism was found outside of the CD11a-EPCR+ fraction indicates that this population contained all HSCs.
We found that the 11a/EPCR method was comparable to the SLAM method of two-color HSC sorting. This is despite the fact that there appeared to be very little overlap between the two populations, with only 12% of CD11a-EPCR+ cells falling Use of CD11a and EPCR to identify HSCs after irradiation or induction of inflammation gave mixed results. The combination appeared to work after irradiation, although total levels of CD11a were upregulated. CD11a upregulation may be involved in HSC differentiation to progenitors, which could be necessary to replenish hematopoietic populations depleted by irradiation, and thus the true undifferentiated HSCs remain CD11a-. As part of LFA-1, CD11a upregulation may also be involved in the migration of HSCs out of their niche and into circulation.
Efficient sorting of mouse HSCs allows in-depth molecular and functional characterization and contributes greatly to our understanding of the biology of these cells.
However, the identification of human HSC markers promises a directly therapeutic impact. Recently, EPCR has been utilized for purification of in vitro expanded human HSCs [26] . Whether or not CD11a can similarly be used for human HSC identification is of great translation interest, and merits further examination. 
